(Source: Johnson & Johnson) Data shows PREZISTA is a safe and effective treatment option in pregnant women, with no reports of mother-to-child HIV transmission among women who continued therapy through delivery TITUSVILLE, NJ, July 18, 2016 - Janssen Therapeutics, Division of Janssen Products, LP (Janssen), today announced that the U.S. Food and Drug Administration (FDA) has approved an expansion to the PREZISTA (darunavir) U.S. Prescribing Information to include data and results from a study investigating the use of PREZISTA during pregnancy and the postpartum period. A human immunodeficiency virus (HIV-1) protease inhibitor, PREZISTA is indicated for the treatment of HIV-1 infection in...
↧